Towards an HIV cure: A global scientific strategy

Nature Reviews Immunology

Volumn 12, Issue 8, 2012, Pages 607-614

  Deeks, Steven G ^a   Autran, Brigitte ^b   Berkhout, Ben ^c   Benkirane, Monsef ^d   Cairns, Scott ^e   Chomont, Nicolas ^f   Chun, Tae Wook ^g   Churchill, Melissa ^h   Mascio, Michele Di ^g   Katlama, Christine ⁱ   Lafeuillade, Alain ^j   Landay, Alan ^k   Lederman, Michael ^l   Lewin, Sharon R ^h   Maldarelli, Frank ^m   Margolis, David ⁿ   Markowitz, Martin ^o   Martinez Picado, Javier ^p   Mullins, James I ^q   Mellors, John ^r   Moreno, Santiago ^s   O'doherty, Una ^t   Palmer, Sarah ^u   Penicaud, Marie Capucine ^e   Peterlin, Matija ^a   Poli, Guido ^v   Routy, Jean Pierre ^w   Rouzioux, Christine ^x   Silvestri, Guido ^y   Stevenson, Mario ^z   Telenti, Amalio ^aa   Lint, Carine Van ^ab   Verdin, Eric ^a   Woolfrey, Ann ^ac   Zaia, John ^ad   Barré Sinoussi, Françoise ^ae   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d INSTITUTE OF HUMAN GENETICS   (France)

^e International AIDS Society   (United States)

^f Vaccine and Gene Therapy Institute of Florida   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h MONASH UNIVERSITY   (Australia)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j GENERAL HOSPITAL   (France)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^p INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^q UNIVERSITY OF WASHINGTON   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s HOSPITAL RAMÓN Y CAJAL   (Spain)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u KAROLINSKA INSTITUTE   (Sweden)

^v University and Scientific Institute   (Italy)

^w MCGILL UNIVERSITY   (Canada)

^x UNIVERSITÉ PARIS DESCARTES   (France)

^y EMORY UNIVERSITY   (United States)

^z UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^aa UNIVERSITY OF LAUSANNE   (Switzerland)

^ab UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^ac Fred Hutchinson Cancer Research Center   (United States)

^ad Beckman Research Institute of City of Hope   (United States)

^ae INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CELL MARKER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS DNA; VIRUS RNA;

BIOASSAY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IN VIVO STUDY; INFECTION CONTROL; MEDICAL SOCIETY; MEMORY T LYMPHOCYTE; NONHUMAN; PATIENT CARE PLANNING; PATIENT MONITORING; PRIORITY JOURNAL; RESERVOIR; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; VIRUS IMMUNITY; VIRUS LATENCY; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HIV INFECTIONS; HUMANS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84864345953     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3262     Document Type: Review

References (80)

1. Phillips, A. N., Neaton, J. & Lundgren, J. D. The role of HIV in serious diseases other than AIDS. AIDS 22, 2409-2418 (2008).
2. UN Secretary-General. Uniting for universal access: towards zero new HIV infections, zero discrimination and zero AIDS-related deaths (United Nations, 2011).
3. Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493-505 (2011).
4. Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009).
5. Trono, D. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174-180 (2010).
6. Cohen, J. The emerging race to cure HIV infections. Science 332, 784-789 (2011).
7. + T cells. Nature Med. 9, 727-728 (2003). (Pubitemid 36749221)
8. Yukl, S. A. et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451-2460 (2010).
9. Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Med. 16, 460-465 (2010).
10. Stebbing, J., Gazzard, B. & Douek, D. C. Where does HIV live? N. Engl. J. Med. 350, 1872-1880 (2004).
11. + T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J. Infect. Dis. 202, 1738-1748 (2010).
12. Kitchen, S. G. & Zack, J. A. CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J. Virol. 71, 6928-6934 (1997). (Pubitemid 27355356)
13. Carter, C. C. et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med. 16, 446-451 (2010).
14. Churchill, M. J. et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 66, 253-258 (2009).
15. Burke, B. et al. Primary cell model for activation-inducible human immunodeficiency virus. J. Virol. 81, 7424-7434 (2007). (Pubitemid 47047831)
16. + T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110, 4161-4164 (2007). (Pubitemid 351377777)
17. + T cells in the absence of activating stimuli. J. Virol. 79, 14179-14188 (2005). (Pubitemid 41552716)
18. + T cells. Blood 113, 58-65 (2009).
19. Marini, A., Harper, J. M. & Romerio, F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 181, 7713-7720 (2008).
20. Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 1868-1877 (2003). (Pubitemid 36460143)
21. Siliciano, R. F. & Greene, W. C. HIV latency. Cold Spring Harb. Perspect. Med. 1, a007096 (2011).
22. Sobhian, B. et al. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell 38, 439-451 (2010).
23. Della Chiara, G. et al. Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. J. Mol. Biol. 410, 933-943 (2011).
24. + cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425-6437 (2010).
25. Williams, S. A. et al. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25, 139-149 (2006). (Pubitemid 43077303)
26. Treand, C. et al. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J. 25, 1690-1699 (2006).
27. Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5, e1000554 (2009).
28. Kauder, S. E., Bosque, A., Lindqvist, A., Planelles, V. & Verdin, E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5, e1000495 (2009).
29. Van Lint, C., Emiliani, S., Ott, M. & Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996). (Pubitemid 26077840)
30. Han, Y. et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4, 134-146 (2008).
31. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Med. 15, 893-900 (2009).
32. + T cells. PLoS Pathog. 7, e1002288 (2011).
33. Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555 (2005). (Pubitemid 41140329)
34. + T cell model without inducing global T cell activation. J. Virol. 85, 6060-6064 (2011).
35. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
36. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782-6789 (2009).
37. + HAART-treated patients. AIDS 19 May 2012 (doi:10.1097/QAD.0b013e32835535f5).
38. Yukl, S. A. et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 202, 1553-1561 (2010).
39. Deleage, C. et al. Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo. Am. J. Pathol. 179, 2397-2408 (2011).
40. Horiike, M. et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 423, 107-118 (2012).
41. Bourry, O. et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 7, 78 (2010).
42. North, T. W. et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84, 2913-2922 (2010).
43. Pillai, S. K. et al. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J. Virol. 79, 1734-1742 (2005). (Pubitemid 40459119)
44. Kwara, A. et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 46, 719-725 (2008). (Pubitemid 351321556)
45. + T cells. J. Exp. Med. 194, 1711-1719 (2001). (Pubitemid 34028651)
46. Clements, J. E. et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J. Infect. Dis. 186, 905-913 (2002).
47. Zeng, M. et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121, 998-1008 (2011).
48. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 12, 1365-1371 (2006). (Pubitemid 44924494)
49. + T cell recovery on antiretroviral therapy. J. Infect. Dis. 203, 1474-1483 (2011).
50. Chun, T. W. et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115, 3250-3255 (2005).
51. Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155 (2011).
52. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501 (2012).
53. Hocqueloux, L. et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24, 1598-1601 (2010).
54. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
55. Hilldorfer, B. B., Cillo, A. R., Besson, G. J., Bedison, M. A. & Mellors, J. W. New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr. HIV/AIDS Rep. 9, 91-100 (2012).
56. Lewin, S. R. & Rouzioux, C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25, 885-897 (2011).
57. Kieffer, T. L. et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452-1465 (2004). (Pubitemid 38543595)
58. Dinoso, J. B. et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 106, 9403-9408 (2009).
59. Gandhi, R. T. et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7, e1000321 (2010).
60. + T cell response. J. Infect. Dis. 203, 960-968 (2011).
61. Sigal, A. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98 (2011).
62. Buzon, M. J. et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog. 7, e1002314 (2011).
63. + T cell activation during HIV infection. Nature Med. 16, 452-459 (2010).
64. Sharova, N., Swingler, C., Sharkey, M. & Stevenson, M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 24, 2481-2489 (2005). (Pubitemid 41032598)
65. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
66. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
67. Brooks, D. G. et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19, 413-423 (2003). (Pubitemid 37153417)
68. Berger, E. A., Moss, B. & Pastan, I. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc. Natl Acad. Sci. USA 95, 11511-11513 (1998). (Pubitemid 28460445)
69. Garcia, F. et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203, 473-478 (2011).
70. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
71. Levy, Y. et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119, 997-1007 (2009).
72. Yang, H. C. et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119, 3473-3486 (2009).
73. + T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc. Natl Acad. Sci. USA 107, 16934-16939 (2010).
74. Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630-634 (2012).
75. Hutter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
76. Allers, K. et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791-2799 (2011).
77. Ananworanich, J. et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 7, e33948 (2012).
78. + cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl Acad. Sci. USA 109, 9523-9528 (2012).
79. Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotech. 28, 839-847 (2010).
80. + cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).